{"id":11517,"date":"2011-07-22T00:17:21","date_gmt":"2011-07-22T04:17:21","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=11517"},"modified":"2011-10-21T23:47:42","modified_gmt":"2011-10-22T03:47:42","slug":"tuning-the-quartet","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2011\/07\/22\/tuning-the-quartet\/","title":{"rendered":"tuning the quartet…"},"content":{"rendered":"
In the course of a long education, there’s an occasional lecture that stands out – sticks in the memory for decades. One of the ones that stuck for me was a statistics lecture in early medical school. Statistics was a minor course, mostly in the curriculum to teach us to read the literature in an informed was. It was the usual – coin flipping, Normal Distribution, T-Tests, only the basics. But there was one lecture with a thousand slides showing graph after graph of fudged and dolled up data. I recall much discussion of scales on the y-axis that didn’t start with zero. The professor had resketched the graphs as they should’ve looked [pre-computer days]. It made an impressive difference. I’ll never forget his final comment. "People who have solid data don’t play with the scales and they never show the ‘standard error of the mean’" [that’s the Stardard Deviation divided by the number of measurements – a way of prettying up a graph]. With that lecture  in mind from the early sixties, here are the studies of the SSRIs in children and adolescents from the early two thousands:<\/div>\n
\n
\n
A Double-blind, Randomized, Placebo-Controlled Trial of Fluoxetine in Children and Adolescents With Depression<\/font><\/strong><\/u>
by Graham J. Emslie, MD; A. John Rush, MD; Warren A. Weinberg, MD; Robert A. Kowatch, MD; Carroll W. Hughes, PhD; Tom Carmody, PhD; and Jeanne Rintelmann<\/sup>
Archives of General Psychiatry<\/font><\/strong>. 1997, 54:1031-1037. <\/div>\n

<\/strong>Abstract<\/strong>
<\/strong><\/p>\n

Background<\/u>: Depression is a major cause of morbidity and mortality in children and adolescents. To date, randomized, controlled, double-blind trials of antidepressants (largely tricyclic agents) have yet to reveal that any antidepressant is more effective than placebo. This article is of a randomized, double-blind, placebo controlled trial of fluoxetine in children and adolescents with depression.
Method<\/u>: Ninety-six child and adolescent outpatients (aged 7-17 years) with nonpsychotic major depressive disorder were randomized (stratified for age and sex) to 20 mg of fluoxetine or placebo and seen weekly for 8 consecutive weeks. Randomization was preceded by 3 evaluation visits that included structured diagnostic interviews during 2 weeks, followed 1 week later by a 1-week, single-blind placebo run-in. Primary outcome measurements were the global improvement of the Clinical Global Impressions scale and the Children’s Depression Rating Scale – Revised, a measure of the severity depressive symptoms.
Results<\/u>: Of the 96 patients, 48 were randomized to fluoxetine treatment and 48 to placebo. Using the intent to treat sample, 27 (56%) of those receiving fluoxetine and 16 (33%) receiving placebo were rated "much" or "very much" improved on the Clinical Global Impressions scale at study exit (chi 2=5.1, df=1, P=.02). Significant differences were also noted in weekly ratings of the Children’s Depression Rating Scale – Revised after 5 weeks of treatment (using last observation carried forward). Equivalent response rates were found for patients aged 12 years and younger (n=48) and those aged 13 years and older (n=48). However, complete symptom remission (Children’s Depression Rating Scale – Revised) occurred in only 31% of the fluoxetine-treated patients and 23% of the placebo patients.
Conclusion<\/u>: <\/sup>Fluoxetine was superior to placebo in the acute phase treatment of major depressive disorder in child and adolescent outpatients with severe, persistent depression<\/sup><\/font><\/strong>. Complete remission of symptoms was rare.<\/sup><\/strong><\/div>\n<\/blockquote>\n
<\/div>\n
\n
\n
Efficacy of Paroxetine in the Treatment of Adolescent Major Depression: A Randomized, Controlled Trial<\/font><\/strong><\/u><\/a>
by MARTIN B. KELLER, M.D., NEAL D. RYAN, M.D., MICHAEL STROBER, PH.D., RACHEL G. KLEIN, PH.D., STAN P. KUTCHER, M.D., BORIS BIRMAHER, M.D., OWEN R. HAGINO, M.D., HAROLD KOPLEWICZ, M.D., GABRIELLE A. CARLSON, M.D., GREGORY N. CLARKE, PH.D., GRAHAM J. EMSLIE, M.D., DAVID FEINBERG, M.D., BARBARA GELLER, M.D., VIVEK KUSUMAKAR, M.D., GEORGE PAPATHEODOROU, M.D., WILLIAM H. SACK, M.D., MICHAEL SWEENEY, PH.D., KAREN DINEEN WAGNER, M.D., PH.D., ELIZABETH B. WELLER, M.D., NANCY C. WINTERS, M.D., ROSEMARY OAKES, M.S., AND JAMES P. MCCAFFERTY, B.S.<\/sup>
Journal of the American Academy of Child and Adolescent Psychiatry<\/font><\/strong>, 2001, 40(7):762–772.<\/div>\n

<\/p>\n

Abstract<\/font><\/strong><\/div>\n
Objective<\/u>:<\/font> To compare paroxetine with placebo and imipramine with placebo for the treatment of adolescent depression.<\/sup><\/strong><\/div>\n
Method<\/u>:<\/font> After a 7 to 14-day screening period, 275 adolescents with major depression began 8 weeks of double-blind paroxetine [20–40 mg], imipramine [gradual upward titration to 200–300 mg], or placebo. The two primary outcome measures were endpoint response [Hamilton Rating Scale for Depression [HAM-D] score <<\/u>8 or ><\/u>50% reduction in baseline HAM-D] and change from baseline HAM-D score. Other depression-related variables were [1] HAM-D depressed mood item; [2] depression item of the Schedule for Affective Disorders and Schizophrenia for Adolescents-Lifetime version [K-SADS-L]; [3] Clinical Global Impression [CGI] improvement scores of 1 or 2; [4] nine-item depression subscale of K-SADS-L; and [5] mean CGI improvement scores.<\/sup><\/strong><\/div>\n
Results<\/u>:<\/font> Paroxetine demonstrated significantly greater improvement compared with placebo in HAM-D total score <<\/u>8, HAM-D depressed mood item, K-SADS-L depressed mood item, and CGI score of 1 or 2. The response to imipramine was not significantly different from placebo for any measure. Neither paroxetine nor imipramine differed significantly from placebo on parent- or self-rating measures. Withdrawal rates for adverse effects were 9.7% and 6.9% for paroxetine and placebo, respectively. Of 31.5% of subjects stopping imipramine therapy because of adverse effects, nearly one third did so because of adverse cardiovascular effects.<\/sup><\/strong><\/div>\n
Conclusions<\/u>:<\/font><\/strong> Paroxetine is generally well tolerated and effective for major depression in adolescents<\/font><\/strong>.<\/sup><\/div>\n<\/blockquote>\n
<\/div>\n
\n
\n
Fluoxetine for Acute Treatment of Depression in Children and Adolescents: A Placebo-Controlled, Randomized Clinical Trial<\/font><\/strong><\/u><\/a>
by GRAHAM J. EMSLIE, M.D., JOHN H. HEILIGENSTEIN, M.D., KAREN DINEEN WAGNER, M.D., PH.D., SHARON L. HOOG, M.D., DANIEL E. ERNEST, B.A., EILEEN BROWN, PH.D., MARY NILSSON, M.S., AND JENNIE G. JACOBSON, PH.D.<\/sup>
Journal of the American Academy of Child and Adolescent Psychiatry<\/font><\/strong>, 2002, 41(10):1205–1215.<\/div>\n

<\/p>\n

Abstract<\/strong>
Method<\/u>: After a 3-week screening period, 122 children and 97 adolescents with MDD (DSM-IV) were randomly assigned to placebo or fluoxetine. After a 1-week placebo lead-in, fluoxetine-treated patients received fluoxetine 10 mg\/day for 1 week, then fluoxetine 20 mg\/day for 8 weeks.
Results<\/u>: Fluoxetine was associated with greater mean improvement in Children’s Depression Rating Scale-Revised (CDRS-R) score than placebo after 1 week (p < .05) and throughout the study period. Significantly more fluoxetine-treated patients (41%) met the prospectively defined criteria for remission than did placebo treated patients (20%) (p < .01). More fluoxetine- (65%) than placebo-treated (53%) patients met the  prospectively defined response criterion of ≥30% decrease in CDRS-R score, but this difference was not significant (p = .093). Significantly more fluoxetine- than placebo-treated patients completed acute treatment (p = .001). There were no significant differences between treatment groups in discontinuations due to adverse events (p = .408).
Conclusion<\/u>: Fluoxetine 20 mg daily appears to be well tolerated and effective for acute treatment of MDD in child and adolescent outpatients.<\/font> Fluoxetine is the only antidepressant that has demonstrated efficacy in two placebo-controlled, randomized clinical trials of pediatric depression.<\/strong><\/sup><\/div>\n<\/blockquote>\n
<\/div>\n
\n
\n
Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials<\/font><\/a><\/strong><\/u>
by Wagner KD, Ambrosini P, Rynn M, Wohlberg C, Yang R, Greenbaum MS, Childress A, Donnelly C, Deas D; and the Sertraline Pediatric Depression Study Group<\/sup>
Journal of the American Medical Association<\/font><\/strong>. 2003, 290(8):1033-41. <\/div>\n

<\/p>\n

Abstract<\/strong><\/div>\n
CONTEXT<\/u>: The efficacy, safety, and tolerability of selective serotonin reuptake inhibitors (SSRIs) in the treatment of adults with major depressive disorder (MDD) are well established. Comparatively few data are available on the effects of SSRIs in depressed children and adolescents.
OBJECTIVE<\/u>: To evaluate the efficacy and safety of sertraline compared with placebo in treatment of pediatric patients with MDD.
DESIGN AND SETTING<\/u>: Two multicenter randomized, double-blind, placebo-controlled trials were conducted at 53 hospital, general practice, and academic centers in the United States, India, Canada, Costa Rica, and Mexico between December 1999 and May 2001 and were pooled a priori.
PARTICIPANTS<\/u>: Three hundred seventy-six children and adolescents aged 6 to 17 years with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition-defined MDD of at least moderate severity.
INTERVENTION<\/u>: Patients were randomly assigned to receive a flexible dosage (50-200 mg\/d) of sertraline (n = 189) or matching placebo tablets (n = 187) for 10 weeks.
MAIN OUTCOME MEASURES<\/u>: Change from baseline in the Children’s Depression Rating Scale-Revised (CDRS-R) Best Description of Child total score and reported adverse events.
RESULTS<\/u>: Sertraline-treated patients experienced statistically significantly greater improvement than placebo patients on the CDRS-R total score (mean change at week 10, -30.24 vs -25.83, respectively; P =.001; overall mean change, -22.84 vs -20.19, respectively; P =.007). Based on a 40% decrease in the adjusted CDRS-R total score at study end point, 69% of sertraline-treated patients compared with 59% of placebo patients were considered responders (P =.05). Sertraline treatment was generally well tolerated. Seventeen sertraline-treated patients (9%) and 5 placebo patients (3%) prematurely discontinued the study because of adverse events. Adverse events that occurred in at least 5% of sertraline-treated patients and with an incidence of at least twice that in placebo patients included diarrhea, vomiting, anorexia, and agitation.
CONCLUSION<\/u>: The results of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term treatment for children and adolescents with MDD<\/font><\/strong>.<\/strong><\/sup><\/div>\n<\/blockquote>\n
<\/div>\n
\n
So with the modern photoshopping, that y-axis scale can be made to start at zero in a heartbeat. The two Prozac Trials on top and Paxil [Trial 329] and Zoloft below [of course, all studies were financed by the respective drug companies]. <\/div>\n

<\/p>\n

 <\/p>\n

My old professor would’ve gone on from there to locate any number of jury rigged features to make these trivial differences shrink even more – things like how drop-outs were handled [particularly the Zoloft study]. Actually, even with the full articles in hand, there are so many obfuscations and missing facts that it’s hard to know if there are any actual differences at all. Oh yeah, none of these articles are forthcoming about the suicidal ideation that emerged along the way.<\/p>\n

Our journals are filled with studies like this – studies where small differences [if even real] end up with conclusions like these:<\/div>\n
    \n
  • \n
    Fluoxetine 20 mg daily appears to be well tolerated and effective for acute treatment of MDD in child and adolescent outpatients<\/font><\/strong><\/div>\n<\/li>\n
  • \n
    Paroxetine is generally well tolerated and effective for major depression in adolescents<\/font><\/strong><\/div>\n<\/li>\n
  • \n
    Fluoxetine was superior to placebo in the acute phase treatment of major depressive disorder in child and adolescent outpatients with severe, persistent depression<\/font><\/strong><\/div>\n<\/li>\n
  • \n
    The results of this pooled analysis demonstrate that sertraline is an effective and well-tolerated short-term treatment for children and adolescents with MDD<\/font><\/strong> <\/div>\n<\/li>\n<\/ul>\n
    I’ve been seeing children and adolescents now for a couple of years. I’ve put a few adolescents on SSRIs with no success. I personally wonder if MDD actually occurs in youth. All the unhappy kids I see have plenty of reason to be unhappy. and I’ve yet to see a case of primary depression in a kid. But that’s hardly the point. These studies were not done for the benefit of unhappy children. They were done in order to tap into the children and adolescent market for pharmaceuticals. We all know that. More to the point – these medications are unlikely to do much for kids no matter what’s wrong with them.<\/div>\n

    So we have a quartet of trials, all shaky, all massaged, all financed by the pharmaceutical company that makes the drug, all written by people ‘on the payroll,’ at least one ghost-written, drugs that we know are ineffective for the advertised condition, all four claiming safety and efficacy. I’m sure my old professor wouldn’t believe what he was reading. What can we do about this state of affairs? The Internet is plenty big – lot’s of room. They could post their raw data so the rest of us could check it out. In fact, if someone has ‘good data,’ we would be glad to tell the world of its goodness.<\/p>\n

    Short of that, at this point in time, all industry funded clinical trials should probably considered analogous to this quartet – lies… <\/div>\n","protected":false},"excerpt":{"rendered":"

    In the course of a long education, there’s an occasional lecture that stands out – sticks in the memory for decades. One of the ones that stuck for me was a statistics lecture in early medical school. Statistics was a minor course, mostly in the curriculum to teach us to read the literature in an […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-11517","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/11517","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=11517"}],"version-history":[{"count":71,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/11517\/revisions"}],"predecessor-version":[{"id":43505,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/11517\/revisions\/43505"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=11517"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=11517"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=11517"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}